Faculty Bibliography

Epidemiologists from the Centers for Disease Control and Prevention have linked the acanthamoeba keratitis outbreak to AMO Complete Moisture Plus Multi-Purpose Solution. Advanced Medical Optics of Santa Ana, Calif., manufactures the solution, which is used to clean and store soft contact lenses

Despite his quick recovery from the seizure he suffered Monday, Chief Justice John Roberts faces a complex diagnosis and a difficult decision. Because the seizure was his second -- he had a similar one in 1993 -- he meets the criteria for epilepsy, and he and his doctors will have to decide whether he should take medication to prevent further seizures, according to neurologists not involved in his care. Neither the chief justice nor his doctors would comment Tuesday

''You're getting pretty old!'' she said, after praising his long service to the country. ''And it's such a hard job!'' Sometimes he can come across on television as subdued, or old-looking, analysts said. Frank Luntz, a Republican strategist who once worked for [Rudolph W. Giuliani], a [John McCain] rival for the nomination, has conducted Fox News focus groups gauging people's reactions to the debates. Some people in his groups used words like ''tired'' and ''old'' to describe Mr. McCain, Mr. Luntz said. So, faced with rivals who are younger, but also have put in far less time in elected office, Mr. McCain tries to make a virtue of his age. ''I'm not the youngest candidate,'' he said in his campaign-kickoff speech. ''But I am the most experienced.''

The two drugs, which could be approved for marketing this year, would add two new classes of drugs to the four that are available to battle HIV, the AIDS virus. That would be especially important to tens of thousands of U.S. patients whose treatment is failing because their virus has become resistant to drugs already in use. While there are now 20 approved drugs to treat HIV and AIDS, there are only four different mechanisms by which the drugs work. In many patients, the rapidly replicating virus evolves resistance to one or more drugs, usually because patients don't take their drugs on time as prescribed

As many Republicans voice frustration about their chances in the 2008 election, a cadre of political allies has been vigorously promoting a candidacy for Mr. [Fred D. Thompson]. A sampling of polls in the last month have placed Mr. Thompson near the top of the Republican field. Dr. [Bruce D. Cheson] said he first examined Mr. Thompson on April 7, 2005, about six months after the former senator had noticed a lump under his jaw. Pathologists at the National Institutes of Health ultimately determined that it was a marginal zone lymphoma, which is an unusual type of a common cancer and affects the immune system. Dr. Cheson said that he could have withheld any therapy for months because the cancer was slow-growing. But Mr. Thompson chose to receive radiation to the neck ''because he did not want to have a visible lump in his neck given his high profile,'' Dr. Cheson said

''The new analyses are both disappointing and puzzling'' because they offer no explanation for the vaccine's failure, said Dr. Anthony S. Fauci, the director of the National Institute of Allergy and Infectious Diseases, a partner in the vaccine trial. The findings raise questions about whether adenovirus can ever be used as a crucial ingredient in an AIDS vaccine and whether new tacks will be needed. Use of a modified virus as a vector to deliver H.I.V. genes is a new and evolving way to make an AIDS vaccine. The Merck vaccine included three synthetic H.I.V. genes. ''We did a beautiful experiment, but it definitely was a disappointment,'' Dr. Larry Corey of the University of Washington, who led the investigators, said in an interview. ''One lesson is that scientists will have to look at vector-based immunity more thoroughly than we have in the past.''

The new reports create even more scientific confusion about how to develop a vaccine to stop the global HIV pandemic, which has infected an estimated 39 million people and killed 25 million more. The findings raise questions about whether adenovirus can ever be used as a crucial ingredient in an AIDS vaccine and whether new tacks will be needed. Use of a modified virus as a vector to deliver HIV genes is a new and evolving way to make an AIDS vaccine. The Merck vaccine included three synthetic HIV genes

The increased risk was principally among a group of people who had pre-existing levels of immunity to a common cold virus known as adenovirus type 5, which was modified to become a critical part of the vaccine. Researchers emphasized that the vaccine itself could not cause AIDS, but one theory is that the cold virus may have activated the immune system in some way to make certain recipients more susceptible to becoming HIV-infected when exposed to the AIDS virus. The vaccine was being tested among 3,000 volunteers at high risk of developing AIDS in nine countries, including those at immunization centers organized by the National Institutes of Health in the United States. Merck's was seen as one of the most promising experimental AIDS vaccines to have been tested on people. Many scientists and AIDS advocates have called the failure of the experimental vaccine a major setback

''It was not watered down in terms of its science,'' Ms. [Dana Perino] said. ''It wasn't watered down in terms of the concerns that climate change raises for public health.'' The testimony that remained said, ''Climate change is anticipated to have a broad range of impacts on the health of Americans and the nation's public health infrastructure.'' But a line saying ''the public health effects of climate change remain largely unaddressed'' was gone, and the testimony focused on the ways health agencies were already prepared to tackle any problems

The Journal of Biological Chemistry initially rejected Dr. Kornberg's two classic papers. He said the journal told him that a peer, the noted scientist Erwin Chargaff, had written ''an exceedingly sarcastic letter'' in assessing his findings. In 1967, Dr. Kornberg and his team became the first to produce the active inner core of a virus in a laboratory. President Lyndon B. Johnson hailed the report of the feat as ''one of the most important stories you ever read'' because it ''opens a wide door to new discoveries in fighting disease and building healthier lives.'' He complained bitterly, however, that too few scientists studied polyphosphate, largely, he said, because of science's proclivity to work ''in a clannish way.'' With more scientists struggling for grants in an era of tight budgets, he said, ''nobody is going to propose doing anything that is bold or creative,'' like working on polyphosphate